Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thrombosomes vs Liquid Stored Platelets in Bleeding Thrombocytopenic Patients
NCT04631211Phase 2Terminated
- Sponsor
- Cellphire Therapeutics, Inc.
- Start
- Mar 2021
- Primary completion
- Jan 2022
- Modality
- Cell Therapies
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of Thrombosomes in Thrombocytopenia, sponsored by Cellphire Therapeutics, Inc. Primary endpoint: Primary Efficacy Endpoint assessed by cessation or decrease in bleeding at 24 hours. Started Mar 2021; status: terminated.
02
Drugs
Thrombosomes
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT04631211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631211.